Catalyst Pharmaceuticals, Inc. (CPRX) on Decifer

Decifer ranks CPRX number 66 of 269 tracked names on durable business quality.

Why it ranks here

• Sales are growing about 20% a year, faster than 68 in 100 companies we measure.
• It keeps about 35 cents of every sales dollar as cash, safer than 95 in 100 companies we measure.
• It earns about 20% a year on the money put into the business, better than 86 in 100 companies we measure.
• It costs about 18 times its yearly profit; the middle of its industry is 21. Cheaper than 64 in 100 companies we measure, against their own industries.

The current read

The evidence on CPRX lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Next-Gen Genetic & RNA/Antibody Therapeutics: Platform breakthroughs in RNA interference, redosable gene therapy and antibody engineering are converting once-undruggable and orphan targets into commercial therapies.

Read the full CPRX research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.